Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 111

1.

Targeting C-reactive protein for the treatment of cardiovascular disease.

Pepys MB, Hirschfield GM, Tennent GA, Gallimore JR, Kahan MC, Bellotti V, Hawkins PN, Myers RM, Smith MD, Polara A, Cobb AJ, Ley SV, Aquilina JA, Robinson CV, Sharif I, Gray GA, Sabin CA, Jenvey MC, Kolstoe SE, Thompson D, Wood SP.

Nature. 2006 Apr 27;440(7088):1217-21.

PMID:
16642000
2.

Limiting myocardial damage during acute myocardial infarction by inhibiting C-reactive protein.

Kitsis RN, Jialal I.

N Engl J Med. 2006 Aug 3;355(5):513-5. No abstract available.

PMID:
16885557
3.

Dissociation of pentameric to monomeric C-reactive protein localizes and aggravates inflammation: in vivo proof of a powerful proinflammatory mechanism and a new anti-inflammatory strategy.

Thiele JR, Habersberger J, Braig D, Schmidt Y, Goerendt K, Maurer V, Bannasch H, Scheichl A, Woollard KJ, von Dobschütz E, Kolodgie F, Virmani R, Stark GB, Peter K, Eisenhardt SU.

Circulation. 2014 Jul 1;130(1):35-50. doi: 10.1161/CIRCULATIONAHA.113.007124. Epub 2014 Apr 28.

4.

C-reactive protein and complement are important mediators of tissue damage in acute myocardial infarction.

Griselli M, Herbert J, Hutchinson WL, Taylor KM, Sohail M, Krausz T, Pepys MB.

J Exp Med. 1999 Dec 20;190(12):1733-40.

5.

Human C-reactive protein increases cerebral infarct size after middle cerebral artery occlusion in adult rats.

Gill R, Kemp JA, Sabin C, Pepys MB.

J Cereb Blood Flow Metab. 2004 Nov;24(11):1214-8.

PMID:
15545914
6.

Recognition functions of pentameric C-reactive protein in cardiovascular disease.

Agrawal A, Gang TB, Rusiñol AE.

Mediators Inflamm. 2014;2014:319215. doi: 10.1155/2014/319215. Epub 2014 May 19. Review.

7.

Chemical knockout of C-reactive protein in cardiovascular disease.

Heinecke JW.

Nat Chem Biol. 2006 Jun;2(6):300-1. No abstract available.

PMID:
16710337
8.

The physiological structure of human C-reactive protein and its complex with phosphocholine.

Thompson D, Pepys MB, Wood SP.

Structure. 1999 Feb 15;7(2):169-77.

9.

Targeting C-Reactive Protein in Inflammatory Disease by Preventing Conformational Changes.

Thiele JR, Zeller J, Bannasch H, Stark GB, Peter K, Eisenhardt SU.

Mediators Inflamm. 2015;2015:372432. doi: 10.1155/2015/372432. Epub 2015 May 18. Review.

10.

Monomeric C-reactive protein modulates classic complement activation on necrotic cells.

Mihlan M, Blom AM, Kupreishvili K, Lauer N, Stelzner K, Bergström F, Niessen HW, Zipfel PF.

FASEB J. 2011 Dec;25(12):4198-210. doi: 10.1096/fj.11-186460. Epub 2011 Aug 19.

PMID:
21856781
11.

Possible mechanisms of C-reactive protein mediated acute myocardial infarction.

Fordjour PA, Wang Y, Shi Y, Agyemang K, Akinyi M, Zhang Q, Fan G.

Eur J Pharmacol. 2015 Aug 5;760:72-80. doi: 10.1016/j.ejphar.2015.04.010. Epub 2015 Apr 18. Review.

PMID:
25895642
12.

C-reactive protein in acute and delayed preconditioning of the rat heart.

Valtchanova-Matchouganska A, Gondwe M, Nadar A.

Cardiovasc J S Afr. 2005 Mar-Apr;16(2):118-23.

13.

Lectin-like oxidized LDL receptor 1 is involved in CRP-mediated complement activation.

Fujita Y, Yamaguchi S, Kakino A, Iwamoto S, Yoshimoto R, Sawamura T.

Clin Chem. 2011 Oct;57(10):1398-405. doi: 10.1373/clinchem.2011.168625. Epub 2011 Aug 5.

14.

The role of C-reactive protein in ischemia/reperfusion injury and preconditioning in a rat model of myocardial infarction.

Valtchanova-Matchouganska A, Gondwe M, Nadar A.

Life Sci. 2004 Jul 9;75(8):901-10.

PMID:
15193950
15.

Inhibition of sPLA2-IIA, C-reactive protein or complement: new therapy for patients with acute myocardial infarction?

Krijnen PA, Meischl C, Nijmeijer R, Visser CA, Hack CE, Niessen HW.

Cardiovasc Hematol Disord Drug Targets. 2006 Jun;6(2):113-23. Review.

PMID:
16787196
16.

C-reactive protein and cardiovascular disease: new insights from an old molecule.

Hirschfield GM, Pepys MB.

QJM. 2003 Nov;96(11):793-807. Review.

PMID:
14566035
17.

Inhibiting C-reactive protein for the treatment of cardiovascular disease: promising evidence from rodent models.

Szalai AJ, McCrory MA, Xing D, Hage FG, Miller A, Oparil S, Chen YF, Mazzone M, Early R, Henry SP, Zanardi TA, Graham MJ, Crooke RM.

Mediators Inflamm. 2014;2014:353614. doi: 10.1155/2014/353614. Epub 2014 Apr 2.

18.

Effect of inflammatory factor-induced cyclo-oxygenase expression on the development of reperfusion-related no-reflow phenomenon in acute myocardial infarction.

Jiao Q, Ke Q, Li W, Jin M, Luo Y, Zhang L, Yang D, Zhang X.

Clin Exp Pharmacol Physiol. 2015 Feb;42(2):162-70. doi: 10.1111/1440-1681.12339.

PMID:
25399887
19.

C-reactive protein colocalizes with complement in human hearts during acute myocardial infarction.

Lagrand WK, Niessen HW, Wolbink GJ, Jaspars LH, Visser CA, Verheugt FW, Meijer CJ, Hack CE.

Circulation. 1997 Jan 7;95(1):97-103.

20.

Complement activation by C-reactive protein on the HEp-2 cell substrate.

Vaith P, Prasauskas V, Potempa LA, Peter HH.

Int Arch Allergy Immunol. 1996 Oct;111(2):107-17.

PMID:
8859218

Supplemental Content

Support Center